Showing 4311-4320 of 9773 results for "".
- Ortho Derm Gets NDA for IDP-123 Lotion for Acnehttps://practicaldermatology.com/news/ortho-derm-gets-nda-for-idp-123-lotion-for-acne-1/2460121/The U.S. Food and Drug Administration (FDA) has accepted Ortho Dermatologic’s New Drug Application for IDP-123 (tazarotene 0.045%) Lotion or acne with a PDUFA action date of Dec. 22, 2019. If approved, IDP-123 will be the first taza
- PE in Dermatology: NavaDerm Partners with Laser & Skin Surgery Center of NYhttps://practicaldermatology.com/news/pe-in-dermatology-navaderm-partners-with-laser-skin-surgery-center-of-ny/2460119/NavaDerm is partnering with Laser & Skin Surgery Center of New York, Midtown Dermatology and their affiliated entities. Navaderm is a dermatology services organization in the Northeast and a BelHealth Investm
- LEO Pharma Completes Acquisition of Bayer’s Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-completes-acquisition-of-bayers-prescription-dermatology-business/2460086/LEO Pharma and Bayer announced the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition
- Positive Top-Line Results Seen in Study of Crisaborole for Mild to Moderate AD in Young Childrenhttps://practicaldermatology.com/news/positive-top-line-results-seen-in-study-of-crisaborole-of-for-mild-to-moderate-ad-in-young-children/2460085/Pfizer’s crisaborole ointment (Eucrisa) was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), according to top-line results from a Phase 4 study (CrisADe CARE 1). The data from the trial are supportive of the primary stud
- Lilly: Taltz Tops Adalimumab for PsA in Head-to-Headhttps://practicaldermatology.com/news/lilly-taltz-tops-adalimumab-for-psa-in-head-to-head/2460069/Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a significantly higher proportion of patients met the primary end
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Crown Laboratories Adds to Portfoliohttps://practicaldermatology.com/news/crown-laboratories-adds-to-portfolio/2460040/On the heels of a brand relaunch this week,Crown Laboratories’ Aesthetics division, Bellus Medical, has acquired the HD PRP system for the aesthetic marketplace from Healeon Medical, Inc. The system is designed to meet the demands of busy practices seeking higher volume and higher yiel
- Study: Teen Acne Linked to Better Gradeshttps://practicaldermatology.com/news/study-teen-acne-linked-to-better-grades/2460038/Individuals who had acne during their teen years earned higher grades in high school and were more likely to complete their bachelor’s degrees, according to a new study in the Journal of Human Capital.
- Blue Lizard Australian Sunscreen Partners with Sesame Workshop, Boston Red Soxhttps://practicaldermatology.com/news/blue-lizard-australian-sunscreen-partners-with-sesame-workshop-boston-red-sox/2460034/Crown Laboratories, Inc’s. Blue Lizard Australian Sunscreen is partnering with Sesame Workshop with a new line of sunscreen for babies and kids. The Sesame Street and Blue Lizard line features Elmo on the mineral-based baby sunscreen
- Nestlé Enters into Negotiations to Sell Nestlé Skin Health to Consortium Led by EQT and ADIAhttps://practicaldermatology.com/news/nestle-enters-into-negotiations-to-sell-nestle-skin-health-to-consortium-led-by-eqt-and-adia/2460031/Nestlé has entered into exclusive negotiations with a consortium led by EQT and a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) for the sale of Nestlé Skin Health for a value of CHF 10.2 billion. Nestlé Skin Health